Mobile website
Basic Research
Characterization of cell-in-cell structure formed between lymphocyte and tumor cell and its biological significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To study the characterization of the cell-in-cell structure formed between heterotypic cells and its biological significance. Methods:By establishing flow cytometry-based analysis and sorting methodology, the formation of heterotypic cell-in-cell structures between human liver cancer PLC/PRF/5 cells and peripheral blood mononuclear cells (PBMCs) was characterized. Based on this step, a method of sorting the cell-in-cell structures and obtaining the cell-in-cell structures formed between mouse splenocytes and PLC/PRF/5 cells was established. Further analysis of the biological characteristic changes of the PLC/PRF/5 cells via plate colony formation assay showed the effect of the cell-in-cell structure formation on PLC/PRF/5 cells. Results: At 4 h and 8 h, the ratio of the cell-in-cell structures formed by activated PBMCs to PLC/PRF/5 tumor cells were apparently higher than that in the inactivated PBMC group (4 h:\[15.75±128\]% vs \[10.56±0.57\]%, P<0.05; 8 h: \[13.49±1.23\]% vs \[11.38±0.97\]%, P<0.05). Besides, the ratio of activated PBMC group at 4 h was still significantly higher than that in the inactivated PBMC group at 8 h (P<005). The colony formation ratio of the sorted cell-in-cell structures formed by mouse splenocytes into PLC/PRF/5 cells was significantly higher than that of PLC/PRF/5 cells (\[32.25±2.32\]% vs \[21.92±2.02\]%, P<0.05). Conclusion: The ratio of cell-in-cell structures formed between activated PBMCs and PLC/PRF/5 cells is higher than that of the inactivated PBMCs, reaching the highest ratio in shorter time. Meanwhile, tumor cells in cell-in-cell structures show an increased colony formation ability in vitro.
Keywords:
Project Supported:
Project supported by the Foundation of Shanghai Science and Technology Committee (No. 10JC1401200)
Clc Number:
